Assuming patients is required, the following results were found.

  • 'We're Just Out of Shape and Weak': What We Heard This Week

    and weak." -- Blogger, emergency physician, and self-proclaimed "gravitologist" Edwin Leap, MD, on why he's seeing more patients with falls at the ED. "The fundamental problem is that it's an unstable molecule." -- David Light, CEO of the online...

    https://mschristian.org/index.php/blog/we-re-just-out-of-shape-and-weak-what-we-heard-this-week
  • Link between gut flora and multiple sclerosis discovered

    synthase. This enzyme is formed in human cells as well as in bacteria frequently found in the gastrointestinal flora of patients suffering from multiple sclerosis. "We believe that the immune cells are activated in the intestine and then migrate to the...

    https://mschristian.org/index.php/blog/link-between-gut-flora-and-multiple-sclerosis-discovered
  • Genentech’s Satralizumab Significantly Reduced Relapse Risk in Second Positive Phase III Study for Neuromyelitis Optica Spectrum Disorder

    placebo in people with neuromyelitis optica spectrum disorder (NMOSD) with aquaporin-4 antibodies (AQP4-IgG seropositive patients) Satralizumab demonstrated a similar safety profile compared to placebo in two Phase III studies across a broad population...

    https://mschristian.org/index.php/blog/genentech-s-satralizumab-significantly-reduced-relapse-risk-in-second-positive-phase-iii-study-for-neuromyelitis-optica-spectrum-disorder
  • Genentech to Present Pivotal Data for Satralizumab in Neuromyelitis Optica Spectrum Disorder and Six-year Ocrevus (Ocrelizumab) Data in Multiple Sclerosis at ECTRIMS

    longer-term data of more than six years to be presented continue to show consistent safety and efficacy outcomes for patients treated with Ocrevus earlier. “Disorders of the nervous system are some of the most complex and difficult to treat, and we have...

    https://mschristian.org/index.php/blog/genentech-to-present-pivotal-data-for-satralizumab-in-neuromyelitis-optica-spectrum-disorder-and-six-year-ocrevus-ocrelizumab-data-in-multiple-sclerosis-at-ectrims
  • Disability progression in multiple sclerosis linked to income, education

    Neighbourhood income and education level is associated with risk of disability progression in patients with multiple sclerosis, suggests new research from the University of British Columbia. UBC researchers, along with colleagues in Wales, compared...

    https://mschristian.org/index.php/blog/disability-progression-in-multiple-sclerosis-linked-to-income-education
  • FDA OKs First Drug for Pediatric Neurofibromas

    1 (NF1). NF1 is a genetic condition that leads to the growth of tumors throughout the body, that while benign can affect patients' organs and be painful and debilitating. Selumetinib, a mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitor, is...

    https://mschristian.org/index.php/articles/2-uncategorised/10544-fda-oks-first-drug-for-pediatric-neurofibromas
  • Novel subtype of multiple sclerosis

    demyelination) was believed to be responsible for nerve cell (neuron) death that leads to irreversible disability in patients with MS. However, in the new findings, a research team led by Bruce Trapp, Ph.D., identified for the first time a subtype of...

    https://mschristian.org/index.php/articles/2-uncategorised/4386-novel-subtype-of-multiple-sclerosis
  • Don't Skip Opiates for ‘Air Hunger’ From COVID-19 Ventilation

    is associated with post-traumatic stress disorder (PTSD)." "With the likelihood that hundreds of thousands of dyspneic patients will require low tidal volume mechanical ventilation around the world, we are concerned about the potential for mass...

    https://mschristian.org/index.php/don-t-skip-opiates-for-air-hunger-from-covid-19-ventilation
  • Study: Certain inflammatory demyelinating diseases belong to different category than multiple sclerosis

    transmission of nerve impulses. This leads to various neurological problems. Scientists have found that some, but not all, patients with inflammatory demyelinating diseases have auto-immune antibodies against myelin oligodendrocyte glycoprotein (MOG),...

    https://mschristian.org/index.php/study-certain-inflammatory-demyelinating-diseases-belong-to-different-category-than-multiple-sclerosis
  • Teenager in Psych Crisis Waits 25 Days in ED for Admission

    told MedPage Today. In the U.S., there are currently 11.7 beds per 100,000 people and 5.4 of those beds are occupied by patients who are being investigated for a crime, according to a widely-cited Treatment Advocacy Center (TAC) report. While there is...

    https://mschristian.org/index.php/articles/2-uncategorised/9719-teenager-in-psych-crisis-waits-25-days-in-ed-for-admission
  • June Halper on How Supportive Team Care Can Help Patients With MS as Their Disability Increases

    care,” this type of care could be called “supportive team care” to better express its potential to educate and care for patients with chronic illnesses such as multiple sclerosis (MS), said June Halper, MSN, APN-C, MSCN, FAAN, chief executive officer,...

    https://mschristian.org/index.php/articles/2-uncategorised/8971-june-halper-on-how-supportive-team-care-can-help-patients-with-ms-as-their-disability-increases
  • Arthritis group offers first guidelines for patients who use CBD for joint pain

    of Michigan. Boehnke helped develop and write the guidelines for the Arthritis Foundation. The group makes it clear that patients should not abandon arthritis medications already prescribed by doctors. "The guidelines are not saying, 'you should try...

    https://mschristian.org/index.php/articles/2-uncategorised/8793-arthritis-group-offers-first-guidelines-for-patients-who-use-cbd-for-joint-pain
  • MS Patients Should Be Informed about Pregnancy Risks and Family Planning, Experts Say

    different aspects of pregnancy, including the risks for the mother and child, and the importance of early counseling for patients wishing to become parents. Until the 1980s, women with MS were discouraged from having children due to the false belief...

    https://mschristian.org/index.php/articles/2-uncategorised/8699-ms-patients-should-be-informed-about-pregnancy-risks-and-family-planning-experts-say
  • Studies Report on Efforts to Optimize Rituximab in MS, NMOSD - The Center for Biosimilars

    to anti-CD20 therapy, but despite the common use of the drug in neurology, there are few data that help guide individual patients’ treatment with rituximab. Important questions remain, such as how long a patient should ideally be treated with rituximab,...

    https://mschristian.org/index.php/articles/2-uncategorised/8691-studies-report-on-efforts-to-optimize-rituximab-in-ms-nmosd-the-center-for-biosimilars
  • Serum NfL Levels May Indicate MS Prodromal Phase

    and neuroaxonal damage may occur already during this phase," Bjornevik stated. Disease processes in MS likely start before patients experience their first symptoms, but little is known about this phase, such as how long it is and what happens during it,...

    https://mschristian.org/index.php/articles/2-uncategorised/8647-serum-nfl-levels-may-indicate-ms-prodromal-phase
  • #ECTRIMS2019 - Transplanting MSCs Safe, Helps Stop Progressive MS - Multiple Sclerosis News Today

    from a single-center clinical trial conducted in Israel. Six months after the transplant, a considerable proportion of patients showed no signs of disease activity, compared to placebo treatment. The findings were shared at the 35th Congress of the...

    https://mschristian.org/index.php/articles/2-uncategorised/8603-ectrims2019-transplanting-mscs-safe-helps-stop-progressive-ms-multiple-sclerosis-news-today
  • Genmab A/S (GMAB) Detailed Results from Phase III ASCLEPIOS I & II Studies of Ofatumumab in Patients with Relapsing MS Presented at ECTRIMS - StreetInsider.com

    News/Genmab AS (GMAB) Detailed Results from Phase III ASCLEPIOS I & II Studies of Ofatumumab in Patients with Relapsing MS Presented at ECTRIMS/15912802.html from 204.152.211.44 on 2019-09-15 15:49:39 UTC. Trace: de673639-1bca-466a-a311-351cd7ee6724 via...

    https://mschristian.org/index.php/articles/2-uncategorised/8602-genmab-a-s-gmab-detailed-results-from-phase-iii-asclepios-i-ii-studies-of-ofatumumab-in-patients-with-relapsing-ms-presented-at-ectrims-streetinsider-com
  • With COVID-19, Stroke Guidelines Now a 'Goal, Not an Expectation'

    To protect stroke team members and patients during the ongoing COVID-19 pandemic, hospitals should aim to follow current guidelines while rethinking resource allocation, according to temporary guidance from the American Heart Association (AHA) and the...

    https://mschristian.org/index.php/articles/2-uncategorised/10492-with-covid-19-stroke-guidelines-now-a-goal-not-an-expectation
  • Most Migraine Patients Lack Treatment

    were diagnosed, and 27.9% received treatment. The percentage of people who received acute treatment ranged from 22.6% of patients with 0-3 monthly headache days to 35% of those with 15 monthly headache days or more. In the preventive analysis, 69.0%...

    https://mschristian.org/index.php/most-migraine-patients-lack-treatment
  • icometrix selected as one of the 150 most innovative digital health startups worldwide by CB Insights - PRNewswire

    CE-marked and FDA-cleared icobrain software, extracts clinically meaningful information from brain MRI and CT scans of patients with neurological disorders, such as multiple sclerosis, Alzheimer's disease, dementia, and brain trauma. The icobrain AI...

    https://mschristian.org/index.php/blog/icometrix-selected-as-one-of-the-150-most-innovative-digital-health-startups-worldwide-by-cb-insights-prnewswire

Results 121 - 140 of 484